Tumour ploidy, response and survival in patients receiving endocrine therapy for advanced breast cancer.
作者信息
Stuart-Harris R, Hedley D W, Taylor I W, Levene A L, Smith I E
出版信息
Br J Cancer. 1985 Apr;51(4):573-6. doi: 10.1038/bjc.1985.80.
Abstract
摘要
相似文献
1
Tumour ploidy, response and survival in patients receiving endocrine therapy for advanced breast cancer.晚期乳腺癌患者接受内分泌治疗时的肿瘤倍体、反应及生存情况
Br J Cancer. 1985 Apr;51(4):573-6. doi: 10.1038/bjc.1985.80.
2
Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.他莫昔芬与氨鲁米特联合应用于绝经后乳腺癌的内分泌及临床后果
Br J Cancer. 1984 Sep;50(3):357-61. doi: 10.1038/bjc.1984.183.
3
Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially.他莫昔芬、氨鲁米特、氢化可的松和达那唑联合或序贯用于治疗播散性乳腺癌。
Lancet. 1984 Jun 23;1(8391):1369-73. doi: 10.1016/s0140-6736(84)91872-5.
4
Second-line hormonotherapy for breast cancer. Uselessness of first-line continuation.乳腺癌的二线激素疗法。一线延续治疗的无用性。
Am J Clin Oncol. 1993 Dec;16(6):522-5. doi: 10.1097/00000421-199312000-00013.
5
Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer.他莫昔芬单独使用或联合氨鲁米特及氢化可的松治疗转移性乳腺癌女性患者的随机试验。
J Clin Oncol. 1986 Jun;4(6):958-64. doi: 10.1200/JCO.1986.4.6.958.
6
7
A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer.他莫昔芬与他莫昔芬联合氨鲁米特治疗绝经后晚期乳腺癌的随机试验。
Cancer Chemother Pharmacol. 1985;14(3):272-3. doi: 10.1007/BF00258132.
8
Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer.他莫昔芬与氨鲁米特及他莫昔芬联合氨鲁米特治疗绝经后晚期乳腺癌的随机试验
Oncology. 1988;45(5):350-3. doi: 10.1159/000226639.
9
A randomized phase II trial of aminoglutethimide and hydrocortisone versus combined aminoglutethimide, hydrocortisone and fluoxymesterone in advanced breast cancer.氨鲁米特与氢化可的松联合应用对比氨鲁米特、氢化可的松及氟羟甲睾酮联合应用治疗晚期乳腺癌的随机II期试验。
Radiother Oncol. 1987 Jul;9(3):217-20. doi: 10.1016/s0167-8140(87)80233-5.
10
Clinical studies with aminoglutethimide in advanced breast carcinoma.氨鲁米特用于晚期乳腺癌的临床研究。
Acta Clin Belg Suppl. 1986;11:29-40.
引用本文的文献
1
Is DNA aneuploidy a good prognostic indicator in patients with advanced colorectal cancer?DNA非整倍体是否是晚期结直肠癌患者的良好预后指标？
Br J Cancer. 1986 Aug;54(2):327-30. doi: 10.1038/bjc.1986.180.
2
Effect of tamoxifen upon cell DNA analysis by flow cytometry in primary carcinoma of the breast.他莫昔芬对乳腺癌原发性肿瘤细胞DNA流式细胞分析的影响。
Br J Cancer. 1987 May;55(5):561-6. doi: 10.1038/bjc.1987.114.
3
Tumour aneuploidy, prognostic parameters and survival in primary breast cancer.原发性乳腺癌中的肿瘤非整倍体、预后参数与生存情况
Br J Cancer. 1987 Apr;55(4):449-54. doi: 10.1038/bjc.1987.88.
4
Tumour DNA ploidy as an independent prognostic factor in breast cancer.肿瘤DNA倍体作为乳腺癌的独立预后因素
Br J Cancer. 1987 Nov;56(5):637-42. doi: 10.1038/bjc.1987.258.
5
Nuclear DNA content and prognosis in human breast cancer: a static cytophotometric study.人类乳腺癌的核DNA含量与预后：一项静态细胞光度学研究。
Breast Cancer Res Treat. 1987;9(2):101-9. doi: 10.1007/BF01807362.
6
DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast.晚期乳腺癌的流式细胞术DNA分析、内分泌治疗反应及预后
Br J Cancer. 1987 May;55(5):553-9. doi: 10.1038/bjc.1987.113.
7
Prognostic value of nuclear DNA content in breast cancer in relation to tumor size, nodal status, and estrogen receptor content.乳腺癌细胞核DNA含量与肿瘤大小、淋巴结状态及雌激素受体含量的预后价值。
Breast Cancer Res Treat. 1989 Jan;13(1):23-32. doi: 10.1007/BF01806547.
8
Aneuploidy as a prognostic factor in breast cancer.非整倍体作为乳腺癌的一个预后因素。
Med Oncol Tumor Pharmacother. 1989;6(2):117-20. doi: 10.1007/BF02985233.
9
Influence of S-phase fraction on metastatic pattern and post-recurrence survival in a randomized mammography screening trial.
Breast Cancer Res Treat. 1989 Dec;14(3):321-7. doi: 10.1007/BF01806304.
10
DNA ploidy level and S-phase fraction as prognostic factors in breast cancer.
Jpn J Surg. 1990 Sep;20(5):491-7. doi: 10.1007/BF02471003.
本文引用的文献
1
Flow cytometry of breast carcinoma: I. Relation of DNA ploidy level to histology and estrogen receptor.乳腺癌的流式细胞术：I. DNA倍体水平与组织学及雌激素受体的关系
Cancer. 1981 Aug 15;48(4):980-4. doi: 10.1002/1097-0142(19810815)48:4<980::aid-cncr2820480421>3.0.co;2-7.
2
Ploidy, proliferative activity and estrogen receptor content in human breast cancer.人类乳腺癌中的倍体、增殖活性和雌激素受体含量
Cytometry. 1982 Jul;3(1):36-41. doi: 10.1002/cyto.990030109.
3
Aminoglutethimide in the treatment of advanced postmenopausal breast cancer.氨鲁米特治疗晚期绝经后乳腺癌。
Cancer Res. 1982 Aug;42(8 Suppl):3405s-3408s.
4
Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma.他莫昔芬与氨鲁米特及他莫昔芬联合氨鲁米特治疗晚期乳腺癌的疗效比较
Cancer Res. 1982 Aug;42(8 Suppl):3430s-3433s.
5
Relationship of steroid receptor, cell kinetics, and clinical status in patients with breast cancer.乳腺癌患者中类固醇受体、细胞动力学与临床状态的关系
Cancer Res. 1981 Sep;41(9 Pt 1):3524-9.
6
Cellular DNA content--a stable feature in epithelial ovarian cancer.细胞DNA含量——上皮性卵巢癌的一个稳定特征。
Br J Cancer. 1984 Feb;49(2):173-9. doi: 10.1038/bjc.1984.29.
7
Prognostic significance of nuclear DNA content in mammary adenocarcinomas in humans.人类乳腺腺癌中核DNA含量的预后意义
Cancer Res. 1984 Jan;44(1):394-6.
8
The influence of age on the DNA ploidy levels of breast tumours.年龄对乳腺肿瘤DNA倍体水平的影响。
Eur J Cancer Clin Oncol. 1983 May;19(5):623-8. doi: 10.1016/0277-5379(83)90178-5.
9
Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.使用流式细胞术分析石蜡包埋病理材料细胞DNA含量的方法。
J Histochem Cytochem. 1983 Nov;31(11):1333-5. doi: 10.1177/31.11.6619538.
10
Influence of cellular DNA content on disease-free survival of Stage II breast cancer patients.细胞DNA含量对II期乳腺癌患者无病生存期的影响。
Cancer Res. 1984 Nov;44(11):5395-8.
Zotero 插件